A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer

Simple item page
dc.check.date2022-07-14
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorZou, Yifang
dc.contributor.authorXiao, Fang
dc.contributor.authorSong, Liu
dc.contributor.authorSun, Bingxue
dc.contributor.authorSun, Dandan
dc.contributor.authorChu, Di
dc.contributor.authorWang, Limei
dc.contributor.authorHan, Shulan
dc.contributor.authorYu, Zhuo
dc.contributor.authorO'Driscoll, Caitríona M.
dc.contributor.authorGuo, Jianfeng
dc.contributor.funderHealth Commission of Jilin Provinceen
dc.contributor.funderEducation Department of Jilin Provinceen
dc.contributor.funderDepartment of Science and Technology of Jilin Provinceen
dc.contributor.funderFundamental Research Funds for the Central Universitiesen
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderEuropean Regional Development Funden
dc.contributor.funderNational Natural Science Foundation of Chinaen
dc.contributor.funderShanghai Shuguang Hospitalen
dc.date.accessioned2021-08-12T14:35:30Z
dc.date.available2021-08-12T14:35:30Z
dc.date.issued2021-07-14
dc.date.updated2021-08-12T14:07:35Z
dc.description.abstractDocetaxel (DTX) is a chemotherapeutic agent used for a range of cancers, but it has little activity against colorectal cancer (CRC). However, combination therapy with other therapeutic agents is a potential strategy to enhance the efficacy of DTX in CRC treatment. The nuclear factor-κB (NF-κB) signaling pathway is implicated in a variety of malignancies (e.g., CRC), and the blockade of NF-κB may increase the sensitivity of cancer cells to chemotherapy. The application of small interference RNA (siRNA) to inhibit the translation of complementary mRNA has demonstrated the potential for cancer gene therapy. In this study, an amphiphilic cationic cyclodextrin (CD) nanoparticle modified with PEGylated folate (FA; a ligand to target folate receptor on CRC) has been developed for co-delivery of DTX and siRNA (against the RelA, a subunit of NF-κB) in the treatment of CRC. The resultant co-formulation (CD.DTX.siRelA.PEG-FA) achieved cell-specific uptake indicating the function of the folate targeting ligand. The CD.DTX.siRelA.PEG-FA nanoparticle enhanced the apoptotic effect of DTX with the downregulation of RelA expression, which significantly retarded the growth of CRC in mice, without causing significant toxicity. These results suggest that the FA-targeted PEGylated CD-based co-formulation provides a promising strategy for combining DTX and siRNA in treating CRC.en
dc.description.sponsorshipHealth Commission of Jilin Province (2020Q012); Education Department of Jilin Province (JJKH20190099KJ); Department of Science and Technology of Jilin Province, China (20170520046JH); National Natural Science Foundation of China (81774240; 82074154) Shanghai Shuguang Hospital (Siming Scholar SGXZ-201904)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid120888en
dc.identifier.citationZou, Y., Xiao, F., Song, L., Sun, B., Sun, D., Chu, D., Wang, L., Han, S., Yu, Z., O'Driscoll, C. M. and Guo, J. (2021) 'A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer', International Journal of Pharmaceutics, 606, 120888 (9pp). doi: 10.1016/j.ijpharm.2021.120888en
dc.identifier.doi10.1016/j.ijpharm.2021.120888en
dc.identifier.endpage9en
dc.identifier.issn1873-3476
dc.identifier.issn0378-5173
dc.identifier.journaltitleInternational Journal of Pharmaceuticsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/11738
dc.identifier.volume606en
dc.language.isoenen
dc.publisherElsevier B.V.en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/en
dc.rights© 2021, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectColorectal canceren
dc.subjectNanoparticleen
dc.subjectChemotherapyen
dc.subjectGene therapyen
dc.subjectCombination therapyen
dc.titleA folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal canceren
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Manuscript_2021-MAR-11.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
Thumbnail Image
Name:
1-s2.0-S0378517321006931-mmc1.docx
Size:
16.19 MB
Format:
Microsoft Word XML
Description:
Appendix A - Supplementary Data
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles